A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.
KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.
Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
A user started using homemade topical finasteride with PG-free liquid minoxidil for hair loss. They noticed the solution became milky with floaters and asked if it needed filtering.
LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.
The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
The user has been experiencing prolonged hair shedding despite using Dutasteride, Minoxidil, and topical Finasteride, with blood tests showing high free testosterone and low SHBG. Suggestions include adjusting Minoxidil dosage, considering topical anti-androgens like RU58841, and addressing metabolic factors to increase SHBG.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
The post and conversation are about a user who made their own Platelet-Rich Plasma (PRP) for hair loss treatment at home, using their own blood and a centrifuge. The responses vary, with some users supporting the DIY approach to save money, others expressing concern about the safety and effectiveness of the method, and a few joking about the lengths people will go to combat hair loss.
The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.
The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.
The user checked iron, ferritin, B12, zinc, testosterone, DHT, and estrogens to understand hair loss causes and the effects of dutasteride. They also noted increased heart rate and paleness with oral minoxidil.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The conversation is about difficulty finding a reputable source for Latanoprost or Bimatoprost in pure powder form or high concentrations for hair loss treatment, with only low concentration solutions being readily available.
RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.